Atrial Fibrillation and PCI - ppt download
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
RE-DUAL PCI™ vs PIONEER AF-PCI™
Complex Coronary Cases - ppt download
AF and PCI in Practice. - ppt download
Dual Antithrombotic Therapy in AF Patients Undergoing PCI - Dr. ten B…
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study | PLOS ONE
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
Atrial Fibrillation and PCI - ppt download
AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups | tctmd.com
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
Objectives, The Site, Finance, and Role of The Ethics Committee, Sponsor and Research Organization
RE-DUAL PCI™ vs PIONEER AF-PCI™
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial - The Lancet
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes - ppt download
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet
